Document is current
Any future updates will be listed below
-
Authors
Tirado, Néstor
Fidyt, Klaudyna
Mansilla, María José
Garcia-Perez, Alba
Martínez-Moreno, Alba
Vinyoles, Meritxell
Alcain, Juan
García-Peydró, Marina
Roca-Ho, Heleia
Fernandez-Fuentes, Narcis
Guerrero-Murillo, Mercedes
Falgàs, Aïda
Velasco-Hernandez, Talia
Bueno, Clara
Panelli, Patrizio
Mulens-Arias, Vladimir
Apostolov, Apostol
Engel, Pablo
González, Europa Azucena
Vick, Binje
Jeremias, Irmela
Caye-Eude, Aurélie
Baruchel, André
Cavé, Hélène
Genescà, Eulàlia
Ribera, Jordi
Díaz-Beyá, Marina
Martínez-Sánchez, María Victoria
Fuster, José Luis
Escudero López, Adela
Minguillón, Jordi
Pérez-Martínez, Antonio
Ramírez-Orellana, Manuel
Torrebadell, Montserrat
Díaz, Víctor M
Toribio, María L
Sánchez-Martínez, Diego
Menéndez, Pablo
- License Information
-
More Information
Article History
Received: 5 November 2024
Accepted: 28 May 2025
First Online: 1 July 2025
Declarations
:
: PM is a cofounder of OneChain Immunotherapeutics, a spin-off company from the Josep Carreras Leukemia Research Institute which has licensed the CCR9 binder (PCT/EP2024/053734). The remaining authors report no conflicts of interest in this work.
